Catalyst sparks price row in US with $300,000 rare disease drugThe controversy over rising drug prices in the US has been reignited after it emerged that the yearly Share XCatalyst sparks price row in US with $300,000 rare disease drughttps://pharmaphorum.com/news/catalyst-sparks-price-row-in-us-with-300000-rare-disease-drug/
Merck’s Keytruda gets boost in kidney and head and neck cancerMerck & Co and its cancer immunotherapy Keytruda has gained a double boost in its tussle with rival Share XMerck’s Keytruda gets boost in kidney and head and neck cancerhttps://pharmaphorum.com/news/mercks-keytruda-gets-boost-in-kidney-and-head-and-neck-cancer/
NHS should invest in digital, AI, and robotics trainingThe Topol Review of the training needs of the future NHS workforce has published its recommendations – including Share XNHS should invest in digital, AI, and robotics traininghttps://pharmaphorum.com/news/nhs-should-invest-in-digital-ai-and-robotics-training/
Gilead NASH drug fails late stage trialGilead’s top late-stage drug selonsertib, for patients with compensated cirrhosis due to nonalcoholic steatohepatitis (NASH), has failed a Share XGilead NASH drug fails late stage trialhttps://pharmaphorum.com/news/gilead-nash-drug-fails-late-stage-trial/
Scotland says no to Yescarta, but backs KymriahScotland’s cost-effectiveness watchdog has decided against making Gilead’s CAR-T therapy Yescarta routinely available to patients with two types Share XScotland says no to Yescarta, but backs Kymriahhttps://pharmaphorum.com/news/scotland-says-no-to-yescarta-but-backs-kymriah/
Janssen’s esketamine depression drug set for key panel voteJanssen’s potential depression treatment made from esketamine – a version of the substance notoriously used illegally as a Share XJanssen’s esketamine depression drug set for key panel votehttps://pharmaphorum.com/news/janssens-esketamine-depression-drug-set-for-key-panel-vote/
Verily builds US drug rehab campus amid opioid crisisAlphabet’s life sciences division Verily is building a rehab campus to help combat the opioid crisis, according to Share XVerily builds US drug rehab campus amid opioid crisishttps://pharmaphorum.com/news/verily-builds-us-drug-rehab-campus-amid-opioid-crisis/
Grey Wolf raises £10m for tumour ‘illumination’ techImmuno-oncology biotech Grey Wolf Therapeutics has raised £10 million in series A financing to develop therapies that increase Share XGrey Wolf raises £10m for tumour ‘illumination’ techhttps://pharmaphorum.com/news/grey-wolf-raises-10m-for-tumour-illumination-tech/
UCB joins with UK charity to research new epilepsy drugsBelgium’s UCB has joined forces with the UK’s Epilepsy Society in a collaboration aimed at finding treatments for Share XUCB joins with UK charity to research new epilepsy drugshttps://pharmaphorum.com/news/ucb-joins-with-uk-charity-to-research-new-epilepsy-drugs/
